Prolonged treatment with large doses of fosfomycin plus vancomycin and amikacin in a case of bacteraemia due to methicillin-resistant Staphylococcus epidermidis and IMP-8 metallo-β-lactamase-producing Klebsiella oxytoca

J Antimicrob Chemother. 2015 Jan;70(1):313-5. doi: 10.1093/jac/dku341. Epub 2014 Sep 1.
No abstract available

Keywords: adverse effects; bacteraemia treatment; carbapenem resistance; carbapenemases; infectious endocarditis.

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Amikacin / administration & dosage*
  • Anti-Bacterial Agents / administration & dosage
  • Bacteremia / drug therapy*
  • Bacteremia / microbiology
  • Bacteremia / pathology
  • Coinfection / drug therapy
  • Coinfection / microbiology
  • Coinfection / pathology
  • Fosfomycin / administration & dosage*
  • Humans
  • Klebsiella Infections / complications
  • Klebsiella Infections / drug therapy*
  • Klebsiella Infections / microbiology
  • Klebsiella Infections / pathology
  • Klebsiella oxytoca / enzymology
  • Klebsiella oxytoca / isolation & purification
  • Male
  • Methicillin Resistance
  • Staphylococcal Infections / complications
  • Staphylococcal Infections / drug therapy*
  • Staphylococcal Infections / microbiology
  • Staphylococcal Infections / pathology
  • Staphylococcus epidermidis / drug effects
  • Staphylococcus epidermidis / isolation & purification
  • Treatment Outcome
  • Vancomycin / administration & dosage*
  • beta-Lactamases / metabolism*

Substances

  • Anti-Bacterial Agents
  • Fosfomycin
  • Vancomycin
  • Amikacin
  • IMP-8 enzyme
  • beta-Lactamases